Ajax announced the closing of an oversubscribed $95 million Series C financing in May 2024, with proceeds being used to support the clinical development of Ajax’s first-in-class Type II JAK2 inhibitor, AJ1‑11095, for the treatment of myelofibrosis, as well as advancing the company’s pipeline of treatments for MPNs.

The company has a unique partnership with Schrödinger, Inc. (NASDAQ: SDGR), the industry leader in molecular simulation software for drug discovery, to develop a pipeline of selectively targeted small molecules.